Literature DB >> 27172353

Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure.

Alina M Allen1, W Ray Kim2.   

Abstract

Chronic liver disease and cirrhosis, a common end result of viral hepatitis, alcohol abuse, and the emerging epidemic of nonalcoholic fatty liver disease are a significant source of morbidity and premature mortality globally. Acute clinical deterioration of chronic liver disease exemplifies the pinnacle of healthcare burden due to the intensive medical needs and high mortality risk. Although a uniformly accepted definition for epidemiological studies is lacking, acute-on-chronic liver failure (ACLF) is increasingly recognized as an important source of disease burden. At least in the United States, hospitalizations for ACLF have increased several fold in the last decade and have a high fatality rate. Acute-on-chronic liver failure incurs extremely high costs, exceeding the yearly costs of inpatient management of other common medical conditions. Although further epidemiological data are needed to better understand the true impact and future trends of ACLF, these data point to the urgency in the clinical investigation for ACLF and the deployment of healthcare resources for timely and effective interventions in affected patients. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27172353     DOI: 10.1055/s-0036-1583201

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  8 in total

1.  Adeno-Associated Virus Serotype 2 Vector-Mediated Reintroduction of microRNA-19b Attenuates Hepatic Fibrosis.

Authors:  Elizabeth Brandon-Warner; Jennifer H Benbow; Jacob H Swet; Nicole A Feilen; Catherine R Culberson; Iain H McKillop; Andrew S deLemos; Mark W Russo; Laura W Schrum
Journal:  Hum Gene Ther       Date:  2018-03-01       Impact factor: 5.695

Review 2.  Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  Transl Gastroenterol Hepatol       Date:  2019-10-11

Review 3.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.

Authors:  Jonel Trebicka; Peer Bork; Aleksander Krag; Manimozhiyan Arumugam
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-30       Impact factor: 46.802

Review 4.  Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

Authors:  Jonel Trebicka; Thomas Reiberger; Wim Laleman
Journal:  Visc Med       Date:  2018-07-13

5.  Editorial: The Risky Business of Fungal Infections in Patients with Cirrhosis.

Authors:  Lisa Brumble; Andrew P Keaveny
Journal:  Am J Gastroenterol       Date:  2018-04       Impact factor: 10.864

Review 6.  Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges.

Authors:  Tian-Tian Li; Ze-Rui Wang; Wei-Qi Yao; En-Qiang Linghu; Fu-Sheng Wang; Lei Shi
Journal:  Stem Cells Transl Med       Date:  2022-09-21       Impact factor: 7.655

Review 7.  Gut-liver axis signaling in portal hypertension.

Authors:  Benedikt Simbrunner; Mattias Mandorfer; Michael Trauner; Thomas Reiberger
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

8.  Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis.

Authors:  Sofia Karkampouna; Danny van der Helm; Mario Scarpa; Bart van Hoek; Hein W Verspaget; Marie-Jose Goumans; Minneke J Coenraad; Boudewijn P T Kruithof; Marianna Kruithof-de Julio
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.